For Investors

Transforming how Europe understands metabolic health

Nutramilo combines clinically-validated AI, nutrigenomics, and real-world medical practice to deliver personalized health insights that prevention deserves.

Request pitch deck Book a call

Market opportunity

$78B

Global personalized health market (2030)

Grand View Research

12.4%

Forecast CAGR for digital health AI

McKinsey Health Tech 2025

67%

Of Europeans want AI-based health insights

EU Digital Health Survey

€42B

European preventive medicine market

Statista 2024

Product and differentiation

Clinically validated AI platform (81/81 tests, 4-layer validation framework)
Expert AI agents: EndoBot, NutriBot, NephroBot, HemoBot
Doctor Portal — the prevention paradigm shift
Patented DIL (Dietary Insulin Load) model — beyond calories
Multi-modal input: lab PDFs, DNA, X-rays, voice journals
Real clinical practice integration (MDC Preventika, Sofia)

Technology stack

Frontend: React 18, TailwindCSS, shadcn/ui
Backend: FastAPI, MongoDB, Pydantic
AI: GPT-5.2 Vision, Whisper STT, multi-agent orchestration
Validation: 4-layer framework (math / physiology / inter-rater / population)
Compliance: GDPR, AES-256, hCaptcha, rate limiting, JWT auth
DevOps: CI/CD pipeline, deployment health checks, monitoring

Team and expertise

Founder with 20+ years in metabolic endocrinology
Clinical consultant: Dr. Lili Ivanova (MDC Preventika)
AI advisory board with peer-reviewed publications
Publishing partner: International Sci Ink Press Ltd.

Current traction

27+

Active AI modules

Clinical calculators

P1–P5

Metabolic phenotypes

BG / EN / ES

Supported languages

1 clinic

Clinical partnerships

Q2 2026

Soft launch

Competitive moat

Bulgaria GLOBOCAN 2024 calibration (regionally unique)
Gail/BCRAT hybrid risk model
Validation framework, peer-review ready
Multilingual, regionally-calibrated insights
Two-sided market — patients + clinicians
Soft moat: Real-world clinician feedback loop (inter-rater study)

Verifiable Science — pip install ours

While MyFitnessPal and Cronometer hide their formulas, ours are public, citation-backed, deterministic — a peer-reviewed Python SDK, installable with one command. This is defensible IP moat that investors can verify in real time.

102/102 tests passing

Pytest regressions for NIS, DIL, UIS, IL ceiling and SDK exports.

n=147 reference dataset

Reproducible Colab notebook — Holt 1997 + Bell 2014 + Bao 2009.

EU AI Act Art. 50 ready

Deterministic rules, no opaque ML — full transparency.

terminal

PyPI ↗

$ pip install nutramilo-nis

MIT License · pypi.org/project/nutramilo-nis · 30+ peer-reviewed PMID citations · 102/102 validations passing.

DOI10.5281/zenodo.20571802 ↗

Use of funds

40%

User base growth — performance marketing, B2B clinic sales

30%

Product development — wearables, mobile apps, Longevity Coach AI

20%

Scientific validation — peer-reviewed publications, retrospective cohorts, SDK reference implementations

10%

Operating expenses and reserve

Current investment round

Pre-seed: €500K – €1.2M

12-month runway, Series A target Q3 2027

Ready for SAFE or equity (investor's choice)

Documentation

Pitch deck (PDF) — on request
Financial model (Excel) — under NDA
Scientific methodology whitepaper (educational positioning, MDR 2017/745 considerations)
Cap table — under NDA

Investor contact

investors@nutramilo.com

International Sci Ink Press Ltd. · Sofia, Bulgaria

We prefer investors with strategic expertise in digital health, longevity, or EU regulatory.